Sheyu Zhang
The Key Laboratory Of Zhejiang Province For Aptamers And Theranostics
Hangzhou, 310022, China
Hangzhou, 310022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Interferon-Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple-Negative Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 01, 2025
PTf-SRiApt Targeting SCAF4-POLR2A Interaction Suppresses Tumor Growth and Promotes Antitumor Immunity in Triple-Negative Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 08, 2025
Chemical evolution of ASO-like DNAzymes for effective and extended gene silencing in cells.
Journal: Nucleic acids research
Published: November 21, 2024
Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions.
Journal: Nature communications
Published: January 11, 2024
A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.
Journal: Cell chemical biology
Published: November 27, 2023
Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
Journal: Cancer
Published: September 20, 2023
Targeting TAF1 with BAY-299 induces antitumor immunity in triple-negative breast cancer.
Journal: Biochemical and biophysical research communications
Published: April 06, 2023
TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer.
Journal: Frontiers in cell and developmental biology
Published: August 16, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026